Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Free Cash Flow (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Free Cash Flow for 11 consecutive years, with -$30.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 110.36% to -$30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$135.1 million through Dec 2025, down 617.24% year-over-year, with the annual reading at -$135.1 million for FY2025, 617.24% down from the prior year.
  • Free Cash Flow hit -$30.9 million in Q4 2025 for Voyager Therapeutics, up from -$31.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $123.5 million in Q1 2023 to a low of -$38.6 million in Q1 2025.
  • Historically, Free Cash Flow has averaged -$7.3 million across 5 years, with a median of -$21.0 million in 2021.
  • Biggest five-year swings in Free Cash Flow: soared 261.36% in 2022 and later crashed 1231.17% in 2024.
  • Year by year, Free Cash Flow stood at $11.1 million in 2021, then tumbled by 196.08% to -$10.7 million in 2022, then crashed by 129.11% to -$24.5 million in 2023, then soared by 40.1% to -$14.7 million in 2024, then crashed by 110.36% to -$30.9 million in 2025.
  • Business Quant data shows Free Cash Flow for VYGR at -$30.9 million in Q4 2025, -$31.3 million in Q3 2025, and -$34.4 million in Q2 2025.